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Cefoperazone-sulbactam plus amikacin empirical therapy
for febrile neutropenia in children with cancer
Aim: To determine the efficacy and safety of cefoperazone-sulbactam combined with amikacin in the
treatment of febrile neutropenia in children with cancer.
Materials and Methods: The study included 20 cancer cases with 26 febrile neutropenia (FEN)
episodes. Patient selection criteria were defined according to the guidelines issued by the Infectious
Disease Society of America (IDSA).
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Results: Patients diagnosed with acute leukemia (58%) and solid tumors (42%) were recorded. Twelve
(46.2%) of the primary disease cases were refractory. The number of infection episodes identified
microbiologically and clinically was 10 (38.5%) and 12 (46.1%), respectively. Fever of unknown origin was
observed in only 4 cases (15.4%). The success rate of the empirical treatment without additional
modification was 42.3% (11 FEN episodes). Four episodes (15.4%) needed a replacement for
sulbactam/cefoperazone because of persistent fever, adverse reactions, and/or clinical deterioration. Three
patients died because of relapse or because they were refractory. As 15 (57.7%) of the patients deteriorated
clinically and had fever, glycopeptide antibiotics were given after 48-72 h. The overall response rate at the
end of the therapy was 80.8%, with/without modification.
Conclusions: The combination of sulbactam/cefoperazone plus amikacin was effective and safe in
the treatment of febrile episodes in neutropenic pediatric cancer patients.
Key words: Neutropenic fever, childhood, cefoperazone/sulbactam, amikacin

Kanserli çocuklardaki ateşli nötropenik hastalar için sefoperazonsulbaktam + amikasin ampirik tedavisi
Amaç: Bu prospektif çalışmanın amacı kanserli çocuklardaki febril nötropenin cefaperazonesulbactam ve amikasin kombinasyonunun etkinliğini saptamaktır.
Yöntem ve Gereç: Bu çalışmaya, toplam 26 febril nötropeni gelişmiş olan 20 hasta dahil edildi. Hasta
seçimi; Amerika İnfeksiyon Hastalıkları Topluluğu tarafından yayınlanmış olan kılavuzdaki tarif
edilmiş olan kriterlere uygun yapıldı.
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Bulgular: Teşhis edilen ve kayıt yapılan hastalar akut lösemi (% 58) ve solid tümörlü (% 42)
hastalardır. Primer hastalığa refrakter olgu sayısı 12 (% 46,2) idi. Mikrobiyolojik ve klinik olarak
saptanan infeksiyon sayısı sırasıyla 10 (% 38,5) ve 12 (% 46,1) idi. Nedeni bilinmeyen ateş sadece 4
vakada (% 15,4) vardı. Ampirik tedavinin başarısı diğer modifikasyon olmaksızın % 42,3 (11 FEN
olayı). 4 FEN’li (% 15,4) hastada ateşin devam etmesi, yan etki ve/veya klinik olarak bozulma
meydana gelmesi nedeniyle ampirik tedavi değiştirilme ihtiyacı oldu. Relaps yada tedaviye cevap
vermediği için üç hasta kaybedildi. Klinik olarak durumu bozulan ve ateşi olan 15 hastaya (% 57,7)
48-72 saat sonra glikopeptid antibiyotik verildi. Tedavinin sonundaki tam cevap oranı,
modifikasyonlu ve modifikasyonsuz olarak % 80,8’dir.
Sonuç: Sulbactam/sefoperazon ve amikasin kombinasyonu çocuk kanser hastalarındaki febril
nötropeni olaylarının tedavisinde etkili ve emniyetlidir.
Anahtar sözcükler: Nötropenik ateş, çocukluk çağı, sefoperazon/sulbaktam, amikasin
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Introduction
The use of intensive chemotherapeutic regimens
produces severe and prolonged neutropenia in many
cancer patients. Neutropenia is known as a major
predisposing factor for the development of infection
in these patients. Management of febrile neutropenic
episodes with early and effective empiric broadspectrum bacterial antibiotic therapy decreases
morbidity and mortality, and is now standard practice
in treating cancer patients with febrile neutropenia
(FEN). Various empiric regimens have been
recommended for therapy (1-4).
B-lactam/B-lactamase inhibitor combinations are a
good choice for empirical antimicrobial therapy in FEN
patients, because their antibacterial spectrum covers
both gram-negative and gram-positive pathogens, and
the addition of the B-lactamase inhibitor overcomes
resistance to B-lactam alone. Sulbactam is one of several
currently available B-lactamase inhibitors that have
intrinsic activity against both gram-positive and gramnegative bacteria. The addition of sulbactam to
cefoperazone enhances cefoperazone’s activity against
B-lactamase, producing some anaerobes, including
Bacteroides fragilis and many aerobic gram-negative
bacilli, and enhances its activity against cefoperazonesusceptible pathogens (5-7).
Aminoglycosides play an important role, especially
in the treatment of gram-negative rod bacteremia in
granulocytopenic patients. Many investigators have
shown that antibiotic combinations of aminoglycoside
and B-lactam, used synergistically to avoid
emergencies caused by resistant bacteria, are more
effective than monotherapy in the treatment of FEN
patients (8,9). Sulbactam/cefoperazone plus amikacin
therapy has not been studied as extensively as the
other combinations, but is reported to be effective and
safe for the empirical treatment of episodes of fever in
neutropenic patients (10).
The purpose of the present prospective study was
to determine the efficacy and safety of
cefoperazone/sulbactam combined with amikacin in
the treatment of FEN in children with cancer.
Materials and methods
We reviewed the medical records of pediatric
cancer patients that experienced episodes of fever and
chemotherapy-induced neutropenia between June
636
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2004 and March 2005. Patient selection criteria were
determined according to the guidelines of the
Infectious Disease Society of America (IDSA):
neutropenia was defined as an absolute neutrophil
count < 500 mm3 or a count < 1000/mm3, but expected
to fall to < 500/mm3 within 48 h; fever was defined as
either a single axillary temperature of at least 38.5 °C
or axillary temperature exceeding 38.0 °C for ≥ 1 h or
twice within a 12-h period (11).
All patients were hospitalized. After complete
history taking, comprehensive clinical and laboratory
evaluations were performed for all patients. Chest
radiographs were obtained. Blood, urine, throat, and
stool cultures were taken before beginning antibiotic
treatment. At least one blood sample was drawn
through the catheter and peripheral vein from each
patient with an indwelling venous catheter. An
antibiogram profile of isolates was made for commonly
used antibiotics. Patients received sulbactam/
cefoperazone 100 mg/kg/day intravenously over 60
min every 8 h (recommended maximum daily dose of
sulbactam was 4 g). This antibiotic was combined with
amikacin 15 mg/kg/day in a single dose.
Each patient and/or parent provided informed
consent prior to inclusion in the study. The study
followed the guidelines of the Helsinki declaration
concerning medical research with humans and
received approval of the local ethics committee. No
support was obtained from the drug manufacturers.
Patients were monitored daily for clinical symptoms.
All patients were assessed 48-72 h after the start of the
empirical therapy, or earlier if clinically indicated. In
cases of unresponsiveness to the therapy, adverse
reactions, a resistant pathogen, or clinical
deterioration, antibiotic treatment was changed or
modified. Vancomycin was added when staphylococci
were grown in culture. The addition of systemic
antifungal therapy was usually considered in cases
unresponsive to broad-spectrum antibiotic therapy
and when clinical symptoms and fever continued for
more than 5 days. Culture samples were repeated
during therapy until fever ceased. Additional chest
radiography was performed in patients that remained
clinically febrile. Invasive diagnostic procedures were
performed on a case-by-case basis. Therapy generally
continued until the granulocyte count increased to >
1000/mm3 or the patient was free of symptoms of
infection for 5 days.
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Data processing
Data are expressed as means (± standard deviation,
SD) or as medians (range). The effects of risk factors on
the duration of treatment and the response to the therapy
were compared using the Mann-Whitney U test.
Results
The study included 20 patients (male/female:
10/10) with a mean age of 6.24 ± 2.8 years (range: 115 years) that had different malignancies (58% acute
leukemia and 42% solid tumors) and 26 FEN episodes
during a 10-month period. Clinical characteristics of
the patients are shown in Table 1. Five patients were
enrolled on more than one occasion (4 patients were
enrolled twice and one patient was enrolled 3 times).
In all, 12 (46.2%) of the patients were unresponsive to
the chemotherapeutic regimens. The initial
granulocyte count in 5 (19.2%) patients was <
100/mm3. Antimicrobial prophylaxis was not used as
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an initial treatment. Two of the patients were given a
central indwelling venous catheter. In all, 10 (38.5%)
and 12 (46.1%) of the infection episodes were
identified
microbiologically
and
clinically,
respectively. Fever of unknown origin was observed
in 4 (15.4%) patients (Table 1).
Table 2 provides a list of the microorganisms
identified in the patients. The results of therapy are
summarized in Table 3. The empirical treatment’s rate
of success without modification was 42.3% (11
episodes). Four episodes (15.4%) required
replacement of sulbactam/cefoperazone with another
antibiotic because of persistent fever, adverse events,
and/or clinical deterioration. Modification of the
initial antibiotic therapy was used in 11 episodes by
the addition of a glycopeptide, antifungal (fluconazole
in 2 episodes and amphotericin B in 4 episodes),
antiviral (acyclovir for herpes labialis in 2 episodes),
metronidazole (in 1 episode), or cotrimoxazole (in 2
episodes).

Table 1. Characteristics of the patients/episodes.
Number (%)
Number of patients
Number of episodes
Underlying malignancy
Solid tumor
Acute leukemia
Age (median/range) (years)
Sex (male/female)
Status of cancer
Remission
Refractory
Entry ANCa severity
< 100/mm3
> 100/mm3
Central indwelling venous catheterb
Patients receiving G-CSFª
Diagnosis of infection episode
Fever of unknown origin (FUO)
Microbiologically documented infection (MDI)
Clinically suspected infection (CDI)
Pneumonia
Upper respiratory tract infection
Gastroenteritis
Mucositis

20
26
11 (42)
15 (58)
6.24 ± 2.8 (1-15)
10/10
14 (53.8)
12 (46.2)
5(19.2)
21 (80.8)
2 (7.6%)
14 (53.8%)
4 (15.4)
10 (38.5) d
12 (46.1)
2
2
3
5

a

ANC: Absolute neutrophil count
One bacteremia case was catheter related
c
G-CSF: Growth colony stimulating factor
d
Multiple microorganisms were identified in 4 patients
b
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Table 2. Microorganisms identified in the patients.
Pathogens

Number

Blood

Staphylococcus aureus
Staphylococcus hominis
Escherichia coli
Burkholderia spp.

1
1
1
1

Urine

Escherichia coli
Non-hemolytic staphylococcus
Proteus mirabilis

1
2
1

Respiratory tract

Pseudomonas aeroginosa

1

Stool

Enterococcus (vancomycin resistant)
Candida albicans
Rotavirus
Enteamobea histolytica

2
1
1
1

Total

14

Multiple microorganisms were identified in 4 patients
* Case 1: 2 sites of infection; ∞ Case 2: 2 sites of infection
∈ Case 3: 2 sites of infection; § Case 4: 3 sites of infection
Table 3. Results of empirical therapy.
Number (%)
Continuing without modification*
Continuing with modification*
Glycopeptide
Antifungal
Antiviral
Others

11 (42.3)
11 (42.3)
11 (42.3)
6 (23)
2 (7.7)
3(11.5)

Change of initial study antibiotic
Results of treatment
Success at 72 h
Success in 7 days
Success with modification
Overall success

4 (15.4)

Failure
Duration of treatment

1(3.8)
15 (57.7)
10 (38.5)
21 (80.8)
5 (19.2)a
9.4 ± 6.1 days
(range: 2-27 days).

*Status at early evaluation (72 h)
a
3 patient that died and 2 that survived needed change of antibiotics

The overall mortality rate was 8.3%; all 3 cases
were refractory. Because of clinical deterioration in
patients (both patients’ initial granulocyte counts were
< 100/mm3) the antibiotic regimens were changed on
638

day 3 and they died due to the progression of
malignancy (primary disease in 1 case was MDSRAEB I and was AML in the other). The third patient
(primary disease was medulloblastoma) died as a
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result of bacteremia due to Staphylococcus aureus
(catheter infection), although initiation was early and
there was no resistance to glycopeptides (initial
granulocyte count was > 100/mm3).
Mean duration of treatment was 9.4 ± 6.1 days
(range: 2-27 days). The duration of hospitalization
increased in episodes with bacteremia and in episodes
with modification of the therapy (Table 3). The
differences between duration of treatment and some
patient features, such as age, cancer type, and gender,
were not significant.
The effect of different parameters on the response
to the therapy was analyzed; disease status, severity of
neutropenia, presence of bacteremia, and antibiotic
modification had an effect. Additionally, 3 factors had
significant prognostic impact on the timing of response
to treatment: presence of mucositis (ulcers of the oral
mucous
membrane),
gastroenteritis,
and
tonsillopharyngitis (hyperemia of the tonsilla and
pharynx associated with rhinitis). All other factors,
such as age, cancer type, and gender, were not
significant predictors of successful treatment of solid or
hematologic malignancies. The status of the underlying
disease affected the length of treatment (P < 0.005).
Skin rash during 1 episode and nausea/vomiting during
2 episodes were observed; hepatic side effects were not
observed after antibiotic treatment.
Discussion
The prompt initiation of empirical antibiotics in
FEN has been the most important advancement in the
protection of cancer patients from sudden death;
therefore, antibiotic regimens that are effective against
the major known pathogens must be selected and
drug resistance should be taken into account while
FEN protocols are prepared. More than 50% of
neutropenic patients with fever have fever of
unknown origin (FUO). In the present study the FUO
rate was 15.4%. In the present study 38.5% and 46.1%
of cases had microbiologically and clinically
confirmed episodes, respectively (Table 1).
Although some recent studies that analyzed the
spectrum of organisms involved in pediatric FEN
cases report that there was a shift from gram-negative
pathogens to gram-positive pathogens, in particular
those caused by Staphylococcus spp. and Streptococcus
spp. gram-negative bacilli, especially P. aeruginosa,
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Escherichia coli, and Klebsiella spp., remain prominent
causes of infection and must be treated with selected
antibiotics (12). In the present study the number of
gram-positive and gram-negative organisms isolated
in cultures was equal. This might have been due to the
rare presence of indwelling central venous catheters
and the absence of pre-therapy prophylaxis in our
patients. We observed that low ANC and
refractoriness were risk factors for prognosis in our
study population. Solid tumors (except hematological
malignancy) and short duration of neutropenia (< 7
days) were risk-assessment factors used for
determining low risk of FEN; however, patients
diagnosed with hematological malignancy and FEN
received combined antibiotic rather than
monotherapy. Although the duration of FEN was not
statistically significant, it was longer in hematological
malignancy patients.
β-lactam/β-lactamase inhibitor combinations are
a good choice for empirical antimicrobial therapy in
FEN patients, because they have an additive or
synergistic bacterial effect with a very broad spectrum
of
activity
against
most
pathogens.
Sulbactam/cefoperazone is effective for empirical
monotherapy in febrile granulocytopenic patients
(13,14). The increased cost effectiveness of
sulbactam/cefoperazone treatment, as compared to
imipenem/cilastatin, is emphasized (10). Another
advantage of sulbactam/cefoperazone is in the
treatment of anaerobic infection. The overall response
rate of sulbactam/cefoperazone plus amikacin was
38% within 72 h of beginning treatment in the present
study. A 57.7% response rate was obtained in less than
7 days with this combination. The overall response
rate was 80.8%, with/without modification, at end of
the therapy. These results confirm both the safety and
efficacy of this treatment protocol, and are in
agreement with previously reported results from other
studies on sulbactam/cefoperazone, with/without the
use other agents (13-20).
Only a few controlled trails evaluating the efficacy
of sulbactam/cefoperazone in a large number of
febrile granulocytopenic patients have been reported.
El Haddad compared sulbactam/cefoperazone with
piperacillin plus amikacin; the response rates were
77% for sulbactam/cefoperazone and 44% for
piperacillin plus amikacin (14). Bodey et al. (17)
reported there was no significant difference in the
639
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overall rates of response to sulbactam/cefoperazone
plus vancomycin (74%) and imipenem plus
vancomycin (73%) in febrile granulocytopenic
patients. In another randomized trial comparing
sulbactam/cefoperazone to imipenem as a
monotherapy for febrile granulocytopenia, Bickers et
al. (19) reported low rates of response to
sulbactam/cefoperazone (44%) and imipenem (33%),
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because of the frequent addition of empirical
amikacin therapy to both antibiotic regimens. Toxicity
related to antibiotics was minimal in the present study.
In conclusion, the present study shows that the
combination of sulbactam/cefoperazone plus
amikacin was effective and safe in the treatment of
febrile episodes in neutropenic cancer patients.
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